After 12 weeks , very high-risk subjects maintained significantly greater achievement of LDL-C < 1.8 mmol/L ( 47 % vs. 35 % ) , non-HDL-C < 2.6 mmol/L ( 63 % vs. 53 % ) and Apo B < 0.8 g/L ( 47 % vs. 38 % ) single targets and dual/triple targets with atorvastatin 10 mg plus ezetimibe vs. atorvastatin 40 mg , while attainment of European target for high-risk subjects was generally similar for both treatments .